Clinical trials: Oligodendroglioma, Childhood
Glioma
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
The primary objective is to evaluate the intratumoral and plasma pharmacokinetics of AC480 among patients who are candidates for a resection with a recurrent malignant glioma who are not on CYP-3A enzyme inducing anti-epileptic…
- Trial name
- NCT00979173
- Testing
- AC480
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Annick Desjardins
Glioma, Astrocytoma
Prolonged Daily Temozolomide for Low-Grade Glioma
The purpose of this trial is to determine the effects (good and bad) temozolomide has on patients with low-grade glioma. It will also determine whether temozolomide is effective in preventing or delaying future tumor growth.
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma
- Trial name
- NCT00165360
- Testing
- Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00003574
- Testing
- surgical procedure, brachytherapy, intraoperative radiation therapy
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033280
- Testing
- temozolomide, neoadjuvant therapy, radiation therapy
- Where
- 39 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Radiation Therapy Oncology Group
Recurrent High Grade Gliomas, Glioblastoma (GBM)
A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
ALERT-1 is a Phase 1/2 study evaluating the safety and preliminary anti-tumor activity of SRN-101, an investigational gene therapy, in adults with recurrent high-grade glioma. High-grade glioma is a type of brain cancer.
- Conditions
- Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- ALERT-1 (NCT07902037)
- Testing
- SRN-101
- Volunteers
- 40 people
- Sponsor
- Siren Biotechnology
Grade II Glioma, Grade III Glioma
Implantable Microdevice In Primary Brain Tumors
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors.
- Conditions
- Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma
- Trial name
- NCT04135807
- Testing
- Microdevice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oliver Jonas
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent…
- Trial name
- NCT00003731
- Testing
- temozolomide
- Where
- 24 sites in Belgium, France and 7 more
- Volunteers
- 39 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Brain and Central Nervous System Tumors, Lymphoma
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003567
- Testing
- filgrastim, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q.
- Conditions
- Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse Midline, H3K27M-mutant
- Trial name
- NCT07608003
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xiangya Hospital of Central South University
Astrocytoma, Glioblastoma Multiforme
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.
- Conditions
- Astrocytoma, Glioblastoma Multiforme, Oligodendroglioma
- Trial name
- NCT05624736
- Testing
- multi-parametric magnetic resonance imaging scan, Pathology examination
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School